Background: Long non-coding RNAs (lncRNAs) are major research factors in a variety of diseases, and lncRNA OIP5-AS1 (OIP5-AS1) was shown to mediate the progression of various tumors. This paper discusses how OIP5-AS1 could potentially be used for diagnosing and prognosticating cholangiocarcinoma (CHOL).
Methods: The ENROCI project evaluated the OIP5-AS1 expression in CHOL samples and confirmed it using RT-qPCR. A bioinformatics database predicted the target gene of OIP5-AS1 in CHOL, which was then confirmed by luciferase activity assays. The CCK-8 and Transwell methods were employed to detect the changes in CHOL cell growth and migration levels after OIP5-AS1 knockdown. ROC and Kaplan-Meier curves were plotted to examine the diagnostic and prognostic functions of OIP5-AS1.
Results: In CHOL tissues and cells, OIP5-AS1 was enhanced compared to the controls. Reducing OIP5-AS1 hampered the regulatory capacity of CHOL cells, and miR-28-5p inhibitor repaired this inhibition. Notably, OIP5-AS1 was observed to sponge and downregulate miR-28-5p, exhibiting high sensitivity and specificity (84.4% and 81.3%) in CHOL. G3BP1 was a direct target of miR-28-5p. Decreased OIP5-AS1 level was beneficial for survival (HR = 2.391, P = 0.024).
Conclusion: OIP5-AS1 targets and negatively mediates miR-28-5p/G3BP1 axis to promote the activity of CHOL cells, which may be a potential marker for diagnosis and prognosis of CHOL patients.